Cargando…

Dysregulated long non-coding RNA in Sjögren’s disease impacts both interferon and adaptive immune responses

OBJECTIVE: Sjögren’s disease (SjD) is an autoimmune disease characterised by inflammatory destruction of exocrine glands. Patients with autoantibodies to Ro/SSA (SjD(Ro+)) exhibit more severe disease. Long non-coding RNAs (lncRNAs) are a functionally diverse class of non-protein-coding RNAs whose ro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joachims, Michelle L, Khatri, Bhuwan, Li, Chuang, Tessneer, Kandice L, Ice, John A, Stolarczyk, Anna M, Means, Nicolas, Grundahl, Kiely M, Glenn, Stuart B, Kelly, Jennifer A, Lewis, David M, Radfar, Lida, Stone, Donald U, Guthridge, Joel M, James, Judith A, Scofield, R Hal, Wiley, Graham B, Wren, Jonathan D, Gaffney, Patrick M, Montgomery, Courtney G, Sivils, Kathy L, Rasmussen, Astrid, Farris, A Darise, Adrianto, Indra, Lessard, Christopher J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Sjögren Syndrome
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717416/ https://www.ncbi.nlm.nih.gov/pubmed/36456101 http://dx.doi.org/10.1136/rmdopen-2022-002672

Ejemplares similares

Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren’s syndrome and non-autoimmune sicca
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
por: Hamkour, Safae, et al.
Publicado: (2023)

Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG
por: Bende, Richard J., et al.
Publicado: (2020)

Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity
por: Hammitt, Katherine M, et al.
Publicado: (2017)

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
por: Hillen, Maarten R, et al.
Publicado: (2020)

Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome
por: Broeren, Mathijs G A, et al.
Publicado: (2022)

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus
por: Trutschel, Diana, et al.
Publicado: (2022)

Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome
por: Pringle, Sarah, et al.
Publicado: (2018)

Genetic variants at the RTP4/MASP1 locus are associated with fatigue in Scandinavian patients with primary Sjögren’s syndrome
por: Norheim, Katrine Brække, et al.
Publicado: (2021)

Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome
por: Verstappen, Gwenny M, et al.
Publicado: (2022)

Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome
por: van Nimwegen, Jolien F., et al.
Publicado: (2020)

Symptom‐Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance
por: McCoy, Sara S., et al.
Publicado: (2022)

Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren’s syndrome-like phenotype in mice
por: Nakamura, Hiroyuki, et al.
Publicado: (2021)

Mixed‐Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients
por: Hackett, Katie L., et al.
Publicado: (2018)

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy
por: Bezzina, Oriana M., et al.
Publicado: (2017)

Application of the OMERACT Grey-scale Ultrasound Scoring System for salivary glands in a single-centre cohort of patients with suspected Sjögren’s syndrome
por: Fana, Viktoria, et al.
Publicado: (2021)

Health-related quality of life and depression among participants in the Sjögren’s International Collaborative Clinical Alliance registry
por: Chou, Annie, et al.
Publicado: (2017)

Hospitalisation rates among patients with primary Sjögren’s syndrome: a population-based study, 1995–2016
por: Maciel, Gabriel, et al.
Publicado: (2018)

Deciphering the role of cDC2s in Sjögren’s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity
por: Lopes, Ana P, et al.
Publicado: (2023)

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome
por: Nayar, Saba, et al.
Publicado: (2019)

Familial Risk of Sjögren's Syndrome and Co‐aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study
por: Kuo, Chang‐Fu, et al.
Publicado: (2015)

Epigenetic Signatures of Salivary Gland Inflammation in Sjögren's Syndrome
por: Cole, Michael B., et al.
Publicado: (2016)

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
por: Posada, James, et al.
Publicado: (2020)

Sjögren’s and non-Sjögren’s sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature
por: Pucino, Valentina, et al.
Publicado: (2022)

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
por: Seror, Raphaele, et al.
Publicado: (2022)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero
por: Hedlund, Malin, et al.
Publicado: (2020)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome
por: Hackett, Kate L, et al.
Publicado: (2019)

Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome
por: Lundtoft, Christian, et al.
Publicado: (2022)

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
por: Rose, Thomas, et al.
Publicado: (2016)

Salivary gland ultrasound abnormalities in primary Sjögren’s syndrome: consensual US-SG core items definition and reliability
por: Jousse-Joulin, Sandrine, et al.
Publicado: (2017)

Cigarette smoking patterns preceding primary Sjögren’s syndrome
por: Mofors, Johannes, et al.
Publicado: (2020)

Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma
por: Pontarini, Elena, et al.
Publicado: (2020)

Antigen-driven selection of antibodies against SSA, SSB and the centromere ‘complex’, including a novel antigen, MIS12 complex, in human salivary glands
por: Takeshita, Masaru, et al.
Publicado: (2020)

Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren’s syndrome
por: Björk, Albin, et al.
Publicado: (2020)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fl0hcvsuqs2g6irhmmkfpsdht7